Literature DB >> 12220649

Novel strategy for anti-HIV-1 action: selective cytotoxic effect of N-myristoyltransferase inhibitor on HIV-1-infected cells.

Nobutoki Takamune1, Hirotoshi Hamada, Shogo Misumi, Shozo Shoji.   

Abstract

N-myristoyltransferase (NMT) is essential for the survival of eukaryotes and the production of infectious human immunodeficiency virus type-1(HIV-1) by the host cell. In this study, we found decreases in the mRNA levels of human NMT isoforms and the NMT activities in the course of HIV-1 infection in the human T-cell line, CEM. Investigating the cytotoxic effect of the novel synthetic NMT inhibitors on the chronic HIV-1 infected T-cell line, CEM/LAV-1, and the uninfected CEM, revealed that the cytotoxic effect was significantly selective for CEM/LAV-1. This was thought to be due to the difference between the NMT levels of the cell lines. In this paper, we propose that NMT may be a candidate target for anti-HIV-1-infected-cell agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220649     DOI: 10.1016/s0014-5793(02)03199-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Recent advances in chemical proteomics: exploring the post-translational proteome.

Authors:  Edward W Tate
Journal:  J Chem Biol       Date:  2008-05-09

2.  Development and characterization of a long-acting nanoformulated abacavir prodrug.

Authors:  Dhirender Singh; JoEllyn McMillan; James Hilaire; Nagsen Gautam; Diana Palandri; Yazen Alnouti; Howard E Gendelman; Benson Edagwa
Journal:  Nanomedicine (Lond)       Date:  2016-07-26       Impact factor: 5.307

3.  Design, synthesis, antiviral activity, and pre-formulation development of poly-L-arginine-fatty acyl derivatives of nucleoside reverse transcriptase inhibitors.

Authors:  Bhanu P Pemmaraju; Swapnil Malekar; Hitesh K Agarwal; Rakesh K Tiwari; Donghoon Oh; Gustavo F Doncel; David R Worthen; Keykavous Parang
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2015       Impact factor: 1.381

Review 4.  Pharmacological Inhibition of Protein Lipidation.

Authors:  Lakshmi Ganesan; Ilya Levental
Journal:  J Membr Biol       Date:  2015-08-18       Impact factor: 1.843

5.  N-Myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef.

Authors:  Kelly E Seaton; Charles D Smith
Journal:  J Gen Virol       Date:  2008-01       Impact factor: 3.891

Review 6.  Myristoylation: An Important Protein Modification in the Immune Response.

Authors:  Daniel Ikenna Udenwobele; Ruey-Chyi Su; Sara V Good; Terry Blake Ball; Shailly Varma Shrivastav; Anuraag Shrivastav
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

7.  Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine.

Authors:  Dongwei Guo; Tian Zhou; Mariluz Araínga; Diana Palandri; Nagsen Gautam; Tatiana Bronich; Yazen Alnouti; JoEllyn McMillan; Benson Edagwa; Howard E Gendelman
Journal:  J Acquir Immune Defic Syndr       Date:  2017-03-01       Impact factor: 3.731

8.  Inhibition of N-myristoyltransferase1 affects dengue virus replication.

Authors:  San Suwanmanee; Yuvadee Mahakhunkijcharoen; Sumate Ampawong; Pornsawan Leaungwutiwong; Dorothée Missé; Natthanej Luplertlop
Journal:  Microbiologyopen       Date:  2019-03-07       Impact factor: 3.139

Review 9.  Protein N-myristoylation: functions and mechanisms in control of innate immunity.

Authors:  Bin Wang; Tong Dai; Wenhuan Sun; Yujun Wei; Jiang Ren; Long Zhang; Mengdi Zhang; Fangfang Zhou
Journal:  Cell Mol Immunol       Date:  2021-03-17       Impact factor: 11.530

10.  Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.

Authors:  Tian Zhou; Hang Su; Prasanta Dash; Zhiyi Lin; Bhagya Laxmi Dyavar Shetty; Ted Kocher; Adam Szlachetka; Benjamin Lamberty; Howard S Fox; Larisa Poluektova; Santhi Gorantla; JoEllyn McMillan; Nagsen Gautam; R Lee Mosley; Yazen Alnouti; Benson Edagwa; Howard E Gendelman
Journal:  Biomaterials       Date:  2017-10-15       Impact factor: 12.479

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.